PUBLISHER: The Business Research Company | PRODUCT CODE: 1720818
PUBLISHER: The Business Research Company | PRODUCT CODE: 1720818
Impetigo is a highly contagious bacterial skin infection primarily caused by *Streptococcus pyogenes*. It typically appears as red sores or blisters that break open, ooze, and develop a yellowish-brown crust. The infection spreads easily through direct skin-to-skin contact or by touching contaminated surfaces.
The primary treatment options for impetigo include topical antibiotics, oral antibiotics, and antiseptic soaks. Oral antibiotics, available in pill or liquid form, are typically prescribed for more severe or widespread infections. The infection can be caused by various pathogens, including Staphylococcus aureus, Streptococcus pyogenes, and other bacteria, with severity ranging from mild to moderate to severe. Impetigo affects different age groups, including children, adults, and the elderly.
The impetigo market research report is one of a series of new reports from The Business Research Company that provides impetigo market statistics, including impetigo industry global market size, regional shares, competitors with an impetigo market share, detailed impetigo market segments, market trends, and opportunities, and any further data you may need to thrive in the impetigo industry. This impetigo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The impetigo market size has grown strongly in recent years. It will grow from $2.25 billion in 2024 to $2.41 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth during the historic period can be attributed to the rising incidence of skin infections, improvements in healthcare infrastructure, increased access to telemedicine, greater public funding for infectious diseases, and the growing demand for topical treatments.
The impetigo market size is expected to see strong growth in the next few years. It will grow to $3.11 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to the expansion of telemedicine and e-pharmacy, government and private sector initiatives, the rising prevalence of skin infections, pediatric population growth, and the increasing demand for dermatology clinics. Key trends expected during this period include advancements in topical treatments, the introduction of novel antimicrobial agents, strategic collaborations and partnerships, regulatory approvals, and pipeline advancements.
The increasing prevalence of skin infections is driving the expansion of the impetigo market. Skin infections occur when harmful microorganisms such as bacteria, viruses, fungi, or parasites invade the skin, leading to irritation, inflammation, or other symptoms. Several factors contribute to the rising occurrence of skin infections, including antibiotic resistance, poor hygiene, climate change, weakened immune systems, and increased global travel. Impetigo treatment plays a crucial role in managing the infection by targeting bacterial pathogens, primarily Streptococcus or Staphylococcus species, using topical or oral antibiotics. This helps alleviate symptoms such as itching and discomfort, prevents the infection from spreading, and accelerates healing, reducing the risk of complications and recurrence. For example, in September 2024, GOV.UK, a UK-based government agency, reported 13,912 cases of Staphylococcus aureus bacteremia during the 2022-2023 financial year, an increase of 7.2% compared to the previous year. As a result, the growing prevalence of skin infections is fueling the demand for impetigo treatments.
The expansion of healthcare facilities is another key driver of the impetigo market. Healthcare facilities, including hospitals, clinics, and diagnostic centers, provide essential medical services to patients. Several factors are contributing to the improvement of healthcare infrastructure, such as increased investments, patient-centered care initiatives, population growth, and aging demographics. Enhanced healthcare facilities support impetigo management by providing better access to specialized dermatological care, expanding the availability of effective treatment options, promoting hygiene practices to prevent infection spread, and enabling early diagnosis and timely intervention. For instance, in May 2023, the American Health Care Association, a US-based nonprofit organization, reported that the United States had 6,129 hospitals, reflecting a 0.59% increase from the previous year. As healthcare facilities improve, the accessibility and effectiveness of impetigo treatment continue to grow.
The rise in healthcare spending is also a significant factor in the expansion of the impetigo market. Healthcare spending includes expenditures on medical care, hospital services, preventive care, medications, research, infrastructure, and administrative costs, all of which contribute to improving individual and public health. Increased healthcare spending is driven by an aging population, advancements in medical technology, a rising prevalence of chronic diseases, and growing demand for healthcare services. In the context of impetigo, higher healthcare expenditure supports the development of innovative treatments, improves access to critical care products, and enhances patient outcomes. For example, in May 2024, the Office for National Statistics, a UK-based government department, reported that UK healthcare spending grew by 5.6% between 2022 and 2023, compared to just 0.9% in 2022. The total healthcare expenditure in the UK reached approximately $317.63 billion (£292 billion) in 2023. Therefore, rising healthcare spending is further accelerating the growth of the impetigo market.
Major players in the impetigo market are Roche Holding AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Galderma SA, Shionogi & Co. Ltd., Dr. Reddy's Laboratories Ltd., Leo Pharma A/S, Torrent Pharmaceuticals Ltd., Almirall S.A, Taro Pharmaceutical Industries Ltd., BioCryst Pharmaceuticals Inc., Melinta Therapeutics Inc., Cutanea Life Sciences Inc., InfectoPharm Arzneimittel und Consilium GmbH, Medimetriks Pharmaceuticals Inc., NovaBay Pharmaceuticals Inc., Ferrer Internacional S.A.
North America was the largest region in the impetigo market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in impetigo report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the impetigo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The impetigo treatment market consists of sales of non-bullous impetigo, and bullous impetigo. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Impetigo Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on impetigo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for impetigo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The impetigo market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.